Strongyloidiasis After Transplant: What You Need to Know to Stay Safe
"Understanding the Risks and Protecting Your Health After a Kidney Transplant"
Kidney transplantation is a life-changing procedure, offering renewed health and vitality to those with end-stage renal disease. However, this significant medical advancement comes with its own set of challenges, including the risk of opportunistic infections. One such infection, strongyloidiasis, caused by the parasite Strongyloides stercoralis, can pose a serious threat to transplant recipients. This article delves into the complexities of strongyloidiasis, providing crucial insights for patients, caregivers, and healthcare professionals.
Strongyloidiasis is a parasitic infection that often goes unnoticed in healthy individuals. But in those with weakened immune systems, like kidney transplant patients, it can become a life-threatening condition. The parasite can spread throughout the body, leading to severe complications. Recognizing the risks and implementing preventive measures are critical for ensuring the long-term health and well-being of transplant recipients.
This article aims to shed light on the challenges of managing strongyloidiasis after kidney transplantation. We'll explore the causes, symptoms, and preventive strategies, offering actionable advice to help you navigate these risks. Our goal is to empower you with the knowledge needed to make informed decisions about your health and to work closely with your healthcare team for the best possible outcomes.
Impact and Available Data
Disseminated strongyloidiasis is potentially life-threatening in organ transplant recipients and is typically reported within the first 6 months after transplantation. A report describes a kidney transplant recipient from Virginia’s Appalachia region who appeared to acquire Strongyloides stercoralis domestically years after transplantation, showing that later presentation can occur. The supplied sources do not provide a population-wide transplant prevalence estimate: the UK source notes no community-level or transplant-clinic prevalence data, while HRSA’s page describes OPTN data reports without giving a Strongyloides figure.
Recognition of Reactivation and Screening
A JAMA report described strongyloidiasis developing in two renal transplant patients and noted the prevailing view that immunosuppression can activate a preexisting Strongyloides infestation, leading to clinical disease. More recent commentary urges clinicians to consider strongyloidiasis in renal transplant recipients who have ever lived in the tropics. It says serological screening, or treatment based on demographic risk factors alone, may be beneficial and should be considered for transplantation guidelines.
Deciphering Strongyloidiasis: Causes, Symptoms, and Risks for Transplant Patients
Strongyloidiasis is caused by the parasitic worm Strongyloides stercoralis, commonly found in tropical and subtropical regions. The parasite enters the body through the skin, often through contact with contaminated soil. Once inside, the larvae migrate to the intestines, where they mature and reproduce. In healthy individuals, the immune system typically keeps the infection under control. However, in transplant patients, the immunosuppressant drugs used to prevent organ rejection can make the body vulnerable to the parasite.
- Skin: Rashes, itching, and redness at the site of entry.
- Lungs: Cough, shortness of breath, and pneumonia.
- Gastrointestinal: Abdominal pain, diarrhea, and nausea.
- Systemic: Fever, weight loss, and fatigue.
Recent Reviews and Donor Screening
A comprehensive review identified 108 episodes of Strongyloides infection among 91 solid organ transplant recipients and 15 hematopoietic cell transplant recipients. A systematic review and meta-analysis of 339 severe cases reports mortality of approximately 87% in severe disease, while noting infection is often asymptomatic in immunocompetent people. Separately, a report on donor-transmitted infections states that, as of October 2025, the Organ Procurement and Transplant Network implemented a new deceased-donor screening policy in the United States to reduce donor-derived Strongyloides risk.
Limits of Testing and Donor Screening
Serologic tests can be useful for Strongyloides diagnosis, but their specificity varies and is difficult to assess because microscopy, used as a reference test, is unreliable. Donor screening can also miss infection: a report of two donor-derived cases in renal transplant recipients says initial donor serologic tests were negative, with retrospective testing later confirming transmission. These findings illustrate limitations in both test interpretation and screening; they do not establish that testing is ineffective in every case.
Reported Outcomes and Study Measures
A pooled review of donor-derived Strongyloides infections reports that 9 of 26 cases with known outcomes resulted in death (34.6%). In a multicenter case-control study, 46 patients met criteria for severe infection—45 kidney transplant recipients and one kidney–pancreas recipient—representing an incidence of 0.29%; they were matched with 92 controls. These figures describe different study populations and measures, so they should not be treated as directly comparable estimates of the same risk.
Empowering Your Health: Key Takeaways and Next Steps
Strongyloidiasis poses a serious risk to kidney transplant recipients, but with awareness, proactive measures, and close collaboration with your healthcare team, you can significantly reduce your risk. Remember to discuss any symptoms with your doctor promptly, follow prescribed medications and preventative strategies, and attend regular follow-up appointments. By staying informed and proactive, you can protect your health and enjoy the benefits of your transplant. Your health is your priority, and with the right knowledge and support, you can navigate the challenges of strongyloidiasis and thrive after your transplant.
Survey of Current Practice
An international survey of screening and management practices for strongyloidiasis in solid organ transplantation describes current approaches for transplant candidates and recipients with, or at risk for, infection. Its authors identify opportunities to improve guidance and optimize care. The supplied summary does not specify particular recommendations or survey results, so it supports a call to strengthen guidance rather than a specific protocol.
A Caution About Unrelated Evidence
The supplied source for this subsection concerns alveolar echinococcosis, not strongyloidiasis. It reports that Belgium was until recently considered at very low risk for alveolar echinococcosis because no human cases had been reported, despite fox infection reaching up to 51% in southern Belgium autopsy series. This evidence cannot establish Strongyloides risk or human impact among transplant recipients.